Document is current
Any future updates will be listed below
-
Authors
Purhonen, Mikko
Tatun, Mikael
Luukkainen, Katariina
Hung, Kevin https://orcid.org/0009-0001-9354-5864
Sundquist, Henri https://orcid.org/0009-0008-8145-9994
Tafjord, Oda
Söderlund, Stina
Adnan-Awad, Shady https://orcid.org/0000-0001-6205-7799
Dohlen, Anni
Heikkinen, Johanna
Koskenvesa, Perttu
Siitonen, Sanna
Mustjoki, Satu https://orcid.org/0000-0002-0816-8241
Shanmuganathan, Naranie https://orcid.org/0000-0001-5895-8797
Bryce, Coral
Danielsson, Signe
Hjorth-Hansen, Henrik https://orcid.org/0000-0002-2670-5696
Olsson-Strömberg, Ulla
Kumagai, Takashi
Kimura, Shinya https://orcid.org/0000-0003-1717-6208
Ross, David M. https://orcid.org/0000-0001-7171-2935
Brück, Oscar https://orcid.org/0000-0002-7842-9419
- License Information
-
More Information
Article History
Received: 21 May 2025
Revised: 13 August 2025
Accepted: 8 September 2025
First Online: 16 September 2025
Competing interests
: OB declares research funding (Pfizer and Gilead Sciences), consultancy fees (AstraZeneca, Novartis, Sanofi, Astellas Pharma, GSK, and Amgen), stock ownership (Cellbytes Ltd). SaS reports stock ownership (Cellbytes Ltd). SA-A reports research funding (Orion Research Foundation). SM reports research funding (BMS, Novartis, Pfizer) and consultancy fees (Novartis, DrenBio) (all unrelated to this study). HH-H reports research funding from Pfizer, Incyte, BMS and Austrian Orphan to the Nordic CML study group (all unrelated to this study). DR has received honoraria from Merck and Novartis and has had an advisory role for Merck, Menarini, Novartis, and Takeda (all unrelated to this study). NS reports honoraria from Novartis and Mallinckrodt.
